Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

M.I.T. Professor Robert Langer Wins European Inventor Award 2016
  • USA - English


News provided by

European Patent Office

Jun 09, 2016, 07:30 ET

Share this article

Share toX

Share this article

Share toX


LISBON, PORTUGAL & CAMBRIDGE, MASS. (PRWEB) June 09, 2016 -- At an awards ceremony held today in Lisbon, Portugal, the European Patent Office (EPO) recognized Massachusetts Institute of Technology (M.I.T) Professor Robert Langer with the European Inventor Award in its “non-European countries” category.

Langer's invention of bioplastic drug delivery has opened up a new approach to fighting some of the most aggressive cancers” -- EPO President Benoît Battistelli.

Post this

Langer was recognized for his development of a new generation of anti-cancer drug therapy that "starves" tumors. Langer invented biodegradable plastics that encapsulate powerful, cancer-fighting drugs that are implanted as wafers directly at tumor sites, allowing for the targeted release of cancer-fighting drugs within a patient’s body. The biodegradable plastics can also be molded into ingestible capsules, cardiovascular stents, as well as into "scaffolding" to support the growth of new body tissue. Langer’s approach has ushered in a new era of targeted therapies: over 20 million patients have been treated with angiogenesis-inhibiting substances. Other therapies derived from Langer's bioplastics have benefited more than one million people.

“Langer's invention of bioplastic drug delivery has opened up a new approach to fighting some of the most aggressive cancers,” said EPO President Benoît Battistelli. “Anti-cancer drugs can be targeted towards tumors for maximum effect without damaging healthy tissue, and the applications are equally impressive in heart surgery and reconstructive medicine.”

TARGETED DELIVERY, MAXIMUM EFFICACY
Langer's approach solves a fundamental problem in cancer therapies. When injected into the bloodstream, highly potent anti-cancer drugs lose effectiveness on their way to the site of the tumor. Even worse, the drugs may harm healthy tissue instead of focusing their effects on fighting disease. This precarious balance is especially important when combatting glioblastoma multiform (GBM), a difficult-to-treat brain cancer surrounded by sensitive nerve tissue. Langer's bioplastics are shaped into "wafers" loaded with cancer-starving drugs that disrupt blood flow to the tumor. Implanted directly above the tumor, thereby bypassing the blood-brain barrier, the drugs are released once the bioplastics are broken down by the body's metabolism.

FROM LABORATORY TO CLINICAL PRACTICE
Langer’s patented invention is the result of decades of dedicated research. In 1971, Langer and fellow physicians at the Massachusetts Institute of Technology (MIT) envisioned a delivery vector that would transport the drugs right where they are needed: the site of the tumor. At first, the scientific community met Langer's bold vision with scepticism. “After my first major scientific talk in 1976, a number of older scientists came up to me and told me: ‘We don’t believe anything you just said,’” said Langer. But Langer, who today heads the world's largest biomedical engineering laboratory, stayed the course. He spent almost 28 years perfecting the implantable bioplastics technology after publishing his initial findings. In the first two years alone, the researcher experimented with over 200 polymer variations.

Scientific expertise and an unparalleled work ethic have made Robert Langer one of the world's most prolific inventors. Named the most-cited engineer in history by Science magazine, he has authored over 13,000 articles and contributed to 1,100 patents, with inventions licensed by 300 pharmaceutical companies.

“My advice to young people is to dream big dreams and don’t give up on those dreams,” says Langer. “Do things that you love doing and also recognize that conventional wisdom is not always correct.”

ABOUT THE EUROPEAN INVENTOR AWARDS
Now in its eleventh year, the prestigious European Inventor Awards are presented annually by the EPO to recognize outstanding inventors from Europe and around the world who have made an exceptional contribution to social development, technological progress and economic growth. The winners were chosen by an independent, international jury out of nearly 400 individuals and teams of inventors put forward for this year's award. The award ceremony, held at Lisbon’s MEO Arena, was opened with keynote addresses by EPO President Benoît Battistelli, Portugal's Prime Minister António Costa, and European Commissioner for Research, Science and Innovation Carlos Moedas. Approximately 600 prominent guests from the fields of politics, business, intellectual property and science were in attendance.

MEDIA MATERIALS FOR ROBERT LANGER:

  • More information about all 15 European Inventor Award finalists (including AV, photo and text materials) is available in the EPO Media Centre.
  • Broadcast-quality (HD) films: English dub and B-roll(via Vimeo).
  • Smart TV users can watch the show on-demand using the "Innovation TV" Smart TV app of the European Patent Office.

Peter Gorman (USA), European Patent Office, http://www.epo.org, +1 617-669-4329, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.